In this episode of the Pharm So Hard Ambulatory Care Podcast, the hosts discuss various studies and trials related to GLP-1 medications for weight management and cardiovascular outcomes. They provide updates on their personal lives and share their experiences with different vehicles, such as Jeeps and Broncos. The studies discussed include the Surmount 1 study, which showed significant weight loss in patients without diabetes; the Risk of Gastrointestinal Adverse Events Associated with GLP-1s study, which highlighted potential side effects of GLP-1 medications; the SELECT trial, which demonstrated the effectiveness of semaglutide in reducing cardiovascular events in patients with obesity and pre-existing cardiovascular disease; and a phase 2 trial of Retro-True Tide, a triple hormone receptor agonist that showed impressive weight loss results. The hosts also discuss the limitations and implications of these studies.

Takeaways

• GLP-1 medications have shown significant weight loss in patients without diabetes.


• GLP-1 medications may have gastrointestinal side effects, but the overall risk is small compared to the potential benefits.


• Semaglutide has been shown to reduce cardiovascular events in patients with obesity and pre-existing cardiovascular disease.


• Retro-True Tide, a triple hormone receptor agonist, has shown impressive weight loss results in a phase 2 trial.


• It is important to consider the limitations and implications of these studies when evaluating the use of GLP-1 medications.